普萘洛尔联合其他治疗措施治疗婴幼儿血管瘤有效率的网状Meta分析

目的:采用网状Meta分析方法,将普萘洛尔联合其他治疗与各对照治疗措施进行对比。方法:以“普萘洛尔”,“血管瘤”为关键词检索CNKI、VIP、万方数据;以“propranolol”“hemangioma”为关键词检索Cochrane Library、Embase、pubmed。检索期限为建库至2019年6月1日。采用STATA14.0软件Network程序包进行数据分析。结果:共纳入18篇文献,涉及8项治疗措施,共纳入1469例血管瘤患者。网状Meta分析结果显示:4种联合治疗方式与单纯口服普萘洛尔相比疗效均优于单纯口服普萘洛尔治疗。普萘洛尔联合注射平阳霉素、普萘洛尔联合外用噻吗洛尔、普萘洛尔联合敷贴器的有效率均优于对应的注射平阳霉素、外用噻吗洛尔及敷贴器。各治疗措施的有效性排序为:普萘洛尔联合敷贴器>普萘洛尔联合外用噻吗洛尔>普萘洛尔联合口服糖皮质激素>普萘洛尔联合注射平阳霉素>敷贴器照射>外用噻吗洛尔>口服普萘洛尔>注射平阳霉素。结论:对于婴幼儿血管瘤的治疗,普萘洛尔联合治疗措施疗效均优于单纯的口服普萘洛尔治疗,其中普萘洛尔联合敷贴器的疗效最佳。     

Three-dimensional finite element analysis of intramedullary nail with different materials in the treatment of intertrochanteric fractures

Intramedullary nails are the common treatment options for femoral intertrochanteric fractures. However, aseptic loosening is considered to be one of the primary forms of failure that can be caused by the stress shielding between the bone and implants. The matching in mechanical properties of implant and bone is a key issue to prevent this failure. Polyetheretherketone (PEEK) and Function-graded (FG) materials are widely used in clinical because of their excellent mechanical properties. In this study, to investigate the biomechanical behaviors of intramedullary nails made of Ti-6Al-4V alloy, Stainless Steel (SS), PEEK and two FG materials, three-dimensional finite element models of intertrochanteric fracture femur with intramedullary nail were constructed with ABAQUS. The maximum von Mises stress on the femoral fracture surface fixed by PEEK intramedullary nail was the largest, followed by FG intramedullary nail, which help stimulate bone growth and subsequently reduce fracture healing time. Compared with traditional metal intramedullary nails, PEEK and FG implants might increase von Mises stress along the same path in the proximal femur. The results showed that PEEK and FG intramedullary nails obviously changed the stress distributions in the bone and reduced stress shielding. This finding indicated that PEEK and FG intramedullary nails have the potential to become alternatives to the conventional metal intramedullary nails.     

miR-147对胶质瘤U87细胞增殖、凋亡和侵袭的影响

目的:比较胶质瘤患者胶质瘤组织和瘤旁组织中miR-147表达水平的差异性，进一步分析miR-147与胶质瘤细胞生物学活性的相关性。方法:通过实时荧光定量PCR检测65例胶质瘤患者瘤组织和瘤旁组织中miR-147的表达水平；采用Lipofectamine 2000转染法转染胶质瘤细胞，分为miR-147 mimics组和NC组，检测两组转染效率；进一步通过CCK-8实验、流式细胞实验和Transwell实验比较两组细胞生物活性。结果:胶质瘤组织中miR-147表达水平显著低于瘤旁组织；与NC组比较，miR-147 mimics组细胞不论是增殖能力还是侵袭能力都明显降低，但是，miR-147 mimics组的细胞凋亡率升高。结论:胶质瘤组织中存在miR-147低表达的现象。miR-147在胶质瘤细胞中表达升高能够抑制细胞的增殖能力、降低其侵袭能力，并促使更多的细胞发生晚期凋亡。miR-147可能在胶质瘤中扮演着抑癌基因的重要角色。     

电灼结合中药内服外洗治疗尖锐湿疣的疗效观察

目的观察电灼结合中药内服外洗治疗尖锐湿疣的临床疗效及对患者T淋巴细胞亚群的影响。方法选择从2013年7月至2017年11月山西医科大学附属大同市第三人民医院泌尿外科治疗尖锐湿疣的患者148例,随机分成对照组和观察组两组,每组74例。对照组患者单独采用电灼治疗;观察组患者在采用电灼基础上结合中药内服外洗共同治疗。结果观察组尖锐湿疣患者复发率为10.8%,低于对照组尖锐湿疣患者复发率28.4%,差异具有统计学意义。(P<0.01)。两组治疗后复发组CD3+细胞、CD4+细胞水平、CD4+/CD8+细胞比值较未复发组低,而CD8+细胞水平较未复发组高,差异具有统计学意义。(P<0.05)。治疗后,观察组尖锐湿疣患者CD3+水平、CD4+水平、CD4+/CD8+比值高于对照组尖锐湿疣患者,且观察组尖锐湿疣患者CD8+水平低于对照组尖锐湿疣患者CD8+水平,差异具有统计学意义(P<0.01)。结论电灼结合中药内服外洗能减少尖锐湿疣的复发率。在临床治疗中,监测尖锐湿疣患者外周血T淋巴细胞亚群,对尖锐湿疣患者治疗后的复发预估及相应增强免疫治疗具有重要的指导意义。     

脑保护下的颈动脉狭窄内支架治疗

目的 评价经皮血管内支架成形术联合应用颈动脉滤器对颈动脉狭窄的治疗效果。方法12例有临床症状的颅外颈动脉狭窄患者接受血管内支架植入治疗，术中同时使用颈动脉滤器进行脑保护，并对颈动脉滤器所回收的物质进行病理学分析。结果12例患者支架及滤器均成功植入，滤器均成功回收。回收物质为微小血栓颗粒、泡沫细胞、胆固醇颗粒。结论经皮血管内支架成形术联合应用颈动脉滤器，可有效缓解颈动脉狭窄所致的血流障碍，预防术中脱落的微小栓子进入脑内。     

卡托普利对血管成形术后再狭窄作用的实验研究

目的探讨卡托普利对血管成形术后再狭窄的干预作用。方法SD雄性大鼠60只,分单损组、干预组和对照组。单损组采用改良导丝法制作大鼠颈动脉再狭窄模型。干预组将卡托普利研磨成粉状,生理盐水稀释配制成5mg/ml溶液,分别于制模前6 d开始按10 mg/(kg.d)剂量经灌胃针给予大鼠至术后各时间点。对侧颈总动脉作为假手术对照组。每组各时间点6只大鼠,于制模后1天、4天、7天、14天及28天原位灌注固定取材。根据HE染色标本情况,选血管形态结构完整的50个标本,进行HE染色,采用病理图像分析系统染色片进行形态计量分析。结果损伤后从第7天起新生内膜厚度和面积逐渐增加,到28天达峰值;与单损组比较,干预组血管壁三层厚度无显著差别,干预组第14、28天新生内膜面积显著减低。狭窄率于血管损伤后逐渐增加,到28天达峰值,与单损组比较,干预组在14天和28天狭窄率明显变小,各时间点内弹力板面积、外弹力板面积及重塑指数两组之间无显著差别。结论卡托普利减小大鼠颈动脉损伤后新生内膜面积及狭窄率,抑制新生内膜形成,但不改变内、外弹力板面积及重塑指数,不影响血管收缩性重塑。     

动脉栓塞治疗产后出血的临床应用研究

目的评价经导管动脉栓塞术(TAE)治疗产后出血的血管造影表现及疗效。方法65例产后出血患者采用右股动脉Seldinger's穿刺技术,选择性插管至双侧髂内动脉或子宫动脉,行数字减影血管造影(DSA)明确出血原因、部位后用庆大霉素浸泡过的明胶海绵颗粒或条栓塞。结果插管成功率100%,手术时间30～60min,平均45.2±4.8min,术后止血总有效率98.46%。术后随访3～60个月,均无严重并发症发生,子宫体按期复旧,转经后月经正常。结论TAE创伤小,疗效快速肯定,对危及生命的产后出血是一种有效的治疗措施。     

Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter,randomized, double-blind,double-dummy,active-controlled,non-inferiority trial

Background/Purpose

Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxacin in patients with CAP.

Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China

BackgroundAlthough the efficacy of hepatitis B vaccines among hemodialysis patients has been documented, the long-term persistence of immunogenicity in this population remains largely unknown. We explored the long-term persistence of immunogenicity induced by different hepatitis B vaccine regimens in hemodialysis patients.MethodsIn initial study, we conducted a randomized, multicenter, double-blind, parallel-controlled trial among hemodialysis patients in 13 hospitals in Shanxi Province, China. A total of 352 hemodialysis patients were allocated to receive 3-dose 20 μg (IM20 group) and 3-dose 60 μg (IM60 group) recombinant hepatitis B vaccine at months 0, 1, and 6. Vaccine-induced immune responses were measured at month 7. In this study, the responders (anti-HBs ≥ 10 mIU/mL) were followed up at months 18, 24, 30, 36 and 42, respectively. We used the generalized log-rank test and generalized estimating equations (GEE) to analyze the long-term durability of responses and the kinetics of anti-HBs levels, respectively.ResultsA total of 284 patients were involved in the extended follow-up period. The duration of vaccine-induced response with 75% of patients maintained protective antibody were 12 months and 18 months in the IM20 group and IM60 group, respectively (P = 0.291). The long-term persistent immunogenicity induced by 3-dose 60 μg was more satisfactory than that by 3-dose 20 μg hepatitis B vaccine in patients with hemodialysis duration ≥ five years (P = 0.023). The peak anti-HBs levels in 100–1000 mIU/mL or ≥ 1000 mIU/mL were more likely to maintain long-term protective antibody compared to anti-HBs levels in 10–100 mIU/mL (P ＜ 0.05). The kinetic profile was similar between the two groups (P = 0.334).ConclusionHigh-dose 60 μg hepatitis B vaccine could lead a satisfactory long-term durability of immunogenicity among patients with hemodialysis duration of five years or more. Peak anti-HBs level after vaccination was associated with the long-term persistence of immunogenicity.